Antimicrobial strategies for the prevention and treatment of cardiovascular infections

Current Opinion in Pharmacology

Volumn 3, Issue 5, 2003, Pages 464-469

  Furuya, E Yoko ^a   Lowy, Franklin D ^a  

^a College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; AMPICILLIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; BACTERIAL VACCINE; BETA LACTAM ANTIBIOTIC; CEFAZOLIN; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; FLUCONAZOLE; LINEZOLID; LIVER ENZYME; LYSOSTAPHIN; METICILLIN; NAFCILLIN; ORITAVANCIN; PENICILLIN G; POLYPEPTIDE ANTIBIOTIC AGENT; PSEUDOMONIC ACID; RIFAMPICIN; SALICYLATE SODIUM; TETRACYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTHRALGIA; ARTIFICIAL HEART PACEMAKER; ASSISTED CIRCULATION; BACTERIAL ENDOCARDITIS; BIOFILM; BONE MARROW SUPPRESSION; CARDIOVASCULAR INFECTION; DEFIBRILLATOR; DRUG POTENTIATION; HEMODIALYSIS; HIGH RISK POPULATION; HUMAN; INFECTION RISK; KIDNEY FAILURE; LIVER DYSFUNCTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MYALGIA; MYCOSIS; MYOPATHY; NEPHROTOXICITY; NONHUMAN; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROSTHESIS INFECTION; REVIEW; THROMBOPHLEBITIS; WOUND INFECTION;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CARDIAC SURGICAL PROCEDURES; CARDIOVASCULAR DISEASES; DEFIBRILLATORS, IMPLANTABLE; DRUG RESISTANCE, BACTERIAL; ENDOCARDITIS, BACTERIAL; HEART-ASSIST DEVICES; HUMANS; PACEMAKER, ARTIFICIAL;

EID: 0141535208     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2003.05.004     Document Type: Review

References (47)

1. National Nosocomial Infections Surveillance (NNIS): System report, data summary from January 1990-May 1999, issued June 1999. Am J Infect Control 1999, 27:520-532.
2. Centers for Disease Control and Prevention: Staphylococcus aureus resistant to vancomycin - United States, 2002. Morb Mortal Wkly Rep 2002, 51:565-567.
3. Fridkin S.K. Hageman J. McDougal L.K. Mohammed J. Jarvis W.R. Perl T.M. Tenover F.C. Vancomycin-Intermediate Staphylococcus aureus Epidemiology Study Group: Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001 Clin Infect Dis 36 2003 429-439
4. Hiramatsu K. Hanaki H. Ino T. Yabuta K. Oguri T. Tenover F.C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility J Antimicrob Chemother 40 1997 135-136
5. Wilson W.R. Karchmer A.W. Dajani A.S. Taubert K.A. Bayer A. Kaye D. Bisno A.L. Ferrieri P. Shulman S.T. Durack D.T. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association J Am Med Assoc 274 1995 1706-1713
6. Olaison L. Schadewitz K. Enterococcal endocarditis in Sweden, 1995-1999: can shorter therapy with aminoglycosides be used? Clin Infect Dis 34 2002 159-166
7. Le T. Bayer A.S. Combination antibiotic therapy for infective endocarditis Clin Infect Dis 36 2003 615-621
8. Horodniceanu T. Bougueleret L. El-Solh N. Bieth G. Delbos F. High-level, plasmid-borne resistance to gentamicin in Streptococcus faecalis subsp. zymogenes Antimicrob Agents Chemother 16 1979 686-689
9. Gavalda J. Torres C. Tenorio C. Lopez P. Zaragoza M. Capdevila J.A. Almirante B. Ruiz F. Borrell N. Gomis X. et al. Efficacy of ampicillin plus ceftriaxone in treatment of experimental endocarditis due to Enterococcus faecalis strains highly resistant to aminoglycosides Antimicrob Agents Chemother 43 1999 639-646
10. Lee K.R. Ring J.C. Leggiadro R.J. Prophylactic antibiotic use in pediatric cardiovascular surgery: a survey of current practice Pediatr Infect Dis J 14 1995 267-269
11. Namias N. Harvill S. Ball S. McKenney M.G. Salomone J.P. Civetta J.M. Cost and morbidity associated with antibiotic prophylaxis in the ICU J Am Coll Surg 188 1999 225-230
12. Harbarth S. Samore M.H. Lichtenberg D. Carmeli Y. Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance Circulation 101 2000 2916-2921
13. Cimochowski G.E. Harostock M.D. Brown R. Bernardi M. Alonzo N. Coyle K. Intranasal mupirocin reduces sternal wound infection after open heart surgery in diabetics and nondiabetics Ann Thorac Surg 71 2001 1572-1579
14. Perl T.M. Cullen J.J. Wenzel R.P. Zimmerman M.B. Pfaller M.A. Sheppard D. Twombley J. French P.P. Herwaldt L.A. Mupirocin and the Risk of Staphylococcus aureus Study Team: Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections N Engl J Med 346 2002 1871-1877
15. Lai K.K. Fontecchio S.A. Infections associated with implantable cardioverter defibrillators placed transvenously and via thoracotomies: epidemiology, infection control, and management Clin Infect Dis 27 1998 265-269
16. Karchmer A.W. Longworth D.L. Infections of intracardiac devices Infect Dis Clin North Am 16 2002 477-505
17. Molina J.E. Undertreatment and overtreatment of patients with infected antiarrhythmic implantable devices Ann Thorac Surg 63 1997 504-509
18. Chua J.D. Wilkoff B.L. Lee I. Juratli N. Longworth D.L. Gordon S. Diagnosis and management of infections involving implantable electrophysiologic cardiac devices Ann Intern Med 133 2000 604-608
19. Oz M.C. Goldstein D.J. Rose E.A. Preperitoneal placement of ventricular assist devices: an illustrated stepwise approach J Card Surg 10 1995 288-294
20. Sivaratnam K. Duggan J.M. Left ventricular assist device infections: three case reports and a review of the literature ASAIO J 48 2002 2-7
21. Vilchez R.A. McEllistrem M.C. Harrison L.H. McCurry K.R. Kormos R.L. Kusne S. Relapsing bacteremia in patients with ventricular assist device: an emergent complication of extended circulatory support Ann Thorac Surg 72 2001 96-101
22. Fischer S.A. Trenholme G.M. Costanzo M.R. Piccione W. Infectious complications in left ventricular assist device recipients Clin Infect Dis 24 1997 18-23
23. Gordon S.M. Schmitt S.K. Jacobs M. Smedira N.M. Goormastic M. Banbury M.K. Yeager M. Serkey J. Hoerscher K. McCarthy P.M. Nosocomial bloodstream infections in patients with implantable left ventricular assist devices Ann Thorac Surg 72 2001 725-730
24. Malani P.N. Dyke D.B.S. Pagani F.D. Chenoweth C.E. Nosocomial infections in left ventricular assist devices Clin Infect Dis 34 2002 1295-1300
25. Nurozler F. Argenziano M. Oz M.C. Naka Y. Fungal left ventricular assist device endocarditis Ann Thorac Surg 71 2001 614-618
26. Gaynes R. Edwards J. The national nosocomial infection surveillance (nnis) system: nosocomial vancomycin-resistant enterococci in the United States, 1989-1995: the first 1000 isolates Infect Control Hosp Epid 17 1996 18
27. Cocito C. Di Giambattista M. Nyssen E. Vannuffel P. Inhibition of protein synthesis by streptogramins and related antibiotics J Antimicrob Chemother 39Suppl A 1997 7-13
28. Moellering R.C. Linden P.K. Reinhardt J. Blumberg E.A. Bompart F. Talbot G.H. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium J Antimicrob Chemother 44 1999 251-261
29. Drew R.H. Perfect J.R. Srinath L. Kurkimilis E. Dowzicky M. Talbot G.H. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin/dalfopristin in patients intolerant of or failing prior therapy J Antimicrob Chemother 46 2000 775-784
30. Moellering R.C. Jr. Linezolid: the first oxazolidinone antimicrobial Ann Intern Med 138 2003 135-142
31. Babcock H.M. Ritchie D.J. Christiansen E. Starlin R. Little R. Stanley S. Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid Clin Infect Dis 32 2001 1373-1375
32. Rao N. White G.J. Successful treatment of Enterococcus faecalis prosthetic valve endocarditis with linezolid Clin Infect Dis 35 2002 902-903
33. Birmingham M.C. Rayner C.R. Meagher A.K. Flavin S.M. Batts D.H. Schentag J.J. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program Clin Infect Dis 36 2003 159-168
34. Tally F.P. DeBruin M.F. Development of daptomycin for gram-positive infections J Antimicrob Chemother 46 2000 523-526
35. Fuchs P.C. Barry A.L. Brown S.D. In vitro bactericidal activity of daptomycin against staphylococci J Antimicrob Chemother 49 2002 467-470
36. Tally F.P. Zeckel M. Wasilewski M.M. Carini C. Berman C.L. Drusano G.L. Oleson F.B. Daptomycin: a novel agent for gram-positive infections Exp Opin Invest Drugs 8 1999 1223-1228
37. Raad I. Intravascular-catheter-related infections Lancet 351 1998 893-898
38. Donlan R.M. Biofilms and device-associated infections Emerg Infect Dis 7 2001 277-281
39. Monzon M. Oteiza C. Leiva J. Amorena B. Synergy of different antibiotic combinations in biofilms of Staphylococcus epidermidis J Antimicrob Chemother 48 2001 793-801
40. Raad I. Alarahwan A. Rolston K. Staphylococcus epidermidis: emerging resistance and need for alternative agents Clin Infect Dis 26 1998 1182-1187
41. Muller E. Al-Attar J. Wolff G. Farber B.F. Mechanism of salicylate-mediated inhibition of biofilm in Staphylococcus epidermidis J Infect Dis 117 1998 501-503
42. Polonio R.E. Mermel L.A. Paquette G.E. Sperry J.F. Eradication of biofilm-forming Staphylococcus epidermidis (RP62A) by a combination of sodium salicylate and vancomycin Antimicrob Agents Chemother 45 2001 3262-3266
43. Climo M.W. Patron R.L. Archer G.L. Combinations of vancomycin and β-lactams are synergistic against Staphylococci with reduced susceptibilities to vancomycin Antimicrob Agents Chemother 43 1999 1747-1753
44. Climo M.W. Patron R.L. Goldstein B.P. Archer G.L. Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis Antimicrob Agents Chemother 42 1998 1355-1360
45. Patron R.L. Climo M.W. Goldstein B.P. Archer G.L. Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced susceptibility to vancomycin Antimicrob Agents Chemother 43 1999 1754-1755
46. Climo M.W. Ehlert K. Archer G.L. Mechanism and suppression of lysostaphin resistance in oxacillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 45 2001 1431-1437
47. Shinefield H. Black S. Fattom A. Horwith G. Rasgon S. Ordonez J. Yeoh H. Law D. Robbins J.B. Schneerson R. et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis N Engl J Med 346 2002 491-496